google-site-verification: googlec7193c3de77668c9.html

Novel endocrine therapy improves disease-free survival over standard of care for patients with early-stage breast cancer

[
The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with the current standard-of-care endocrine therapy in patients with early-stage, hormone receptor (HR)-positive, HER2-negative breast cancer, according to the results of a Phase III IidERA trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9–12, 2025.


Source link

Advertisements
Views: 2

See also  'I'm deprived of my UK citizenship but I'm not a convicted terrorist' | World News

Check Also

New cases slow in NYC Legionnaires’ disease outbreak; Met museum among buildings with positive tests

[ This 1978 electron microscope image made available by the Centers for Disease Control and …

Brain-computer training sharpens detection of tiny movement errors in five days

[ Credit: Pixabay/CC0 Public Domain The brain uses visual cues to coordinate muscle movement. When …

Why are family doctors leaving the workforce? Retirement, burnout creating a US primary care 'brain drain'

[ A bad back led Dr. Dale Block to retire from family medicine in 2019 …

Leave a Reply

Available for Amazon Prime
elfbar elfa kit. elfbar elfx kit dark sea.